This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n7https://global.dbpedia.org/id/
yagohttp://dbpedia.org/class/yago/
dbthttp://dbpedia.org/resource/Template:
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
freebasehttp://rdf.freebase.com/ns/
n13http://www.grid.ac/institutes/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbchttp://dbpedia.org/resource/Category:
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
goldhttp://purl.org/linguistics/gold/
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:ACELL
dbo:wikiPageWikiLink
dbr:ACell
dbo:wikiPageDisambiguates
dbr:ACell
Subject Item
dbr:ACell
rdf:type
yago:YagoPermanentlyLocatedEntity yago:YagoLegalActor yago:YagoLegalActorGeo yago:Group100031264 yago:Abstraction100002137 dbo:Company yago:Institution108053576 yago:Company108058098 yago:Organization108008335 yago:SocialGroup107950920 yago:WikicatBiotechnologyCompaniesOfTheUnitedStates
rdfs:label
ACell
rdfs:comment
ACell is a Columbia, Maryland-based biotechnology company. The company works in regenerative medicine, in which it owns several extracellular matrix patents. ACell develops, manufactures and markets products for medical and veterinary applications. The company was founded by Alan R. Spievack, a former associate professor at Harvard Medical School and is currently run by Patrick A. McBrayer. Over 100 papers have been published related to the use of ACell's MatriStem UBM.
dcterms:subject
dbc:2021_mergers_and_acquisitions dbc:Biotechnology_companies_of_the_United_States
dbo:wikiPageID
17210298
dbo:wikiPageRevisionID
1072514399
dbo:wikiPageWikiLink
dbr:Basement_membrane dbr:Lamina_propria dbr:Integra_LifeSciences dbr:Jessup,_Maryland dbr:Harvard_Medical_School dbr:Patent dbc:2021_mergers_and_acquisitions dbr:Tulane_University dbr:Extracellular_matrix dbr:Esquire_(magazine) dbr:Pig_bladder dbr:Regenerative_medicine dbr:Biotechnology dbr:Controlled_study dbc:Biotechnology_companies_of_the_United_States
owl:sameAs
n7:4JtkW wikidata:Q4650965 yago-res:ACell freebase:m.043s3jv
dbp:wikiPageUsesTemplate
dbt:Other_uses dbt:Reflist
dbo:abstract
ACell is a Columbia, Maryland-based biotechnology company. The company works in regenerative medicine, in which it owns several extracellular matrix patents. ACell develops, manufactures and markets products for medical and veterinary applications. The company was founded by Alan R. Spievack, a former associate professor at Harvard Medical School and is currently run by Patrick A. McBrayer. ACell's extracellular matrix (ECM) is derived from the lamina propria and basement membrane of a porcine Urinary Bladder Matrix (UBM). The lamina propria acts as a scaffold for cell infiltration while the basement membrane encourages the growth of site-specific tissue as the UBM resorbs. The UBM is offered in both sheet and powder form. The powder form is sold under the brand name of MicroMatrix. The company offers products for wound management (Cytal and MicroMatrix), hernia repair (Gentrix) and Pelvic Organ Prolapse repair (Pelvic Floor Matrix). Over 100 papers have been published related to the use of ACell's MatriStem UBM. ACell's use of porcine cellular structure, called MatriStem, as a scaffold for human tissue regeneration was named the "medical breakthrough of the year" by Esquire. The use of pig bladder ground up into "magical pixie dust" to regrow Spievak's brother's finger received considerable mainstream coverage. Ken Muneoka of Tulane University, who works with ACell's scientific advisors on US-government funded investigations into regenerative medicine, said that the news should be viewed with caution because it was not a controlled study. In January 2021, Integra LifeSciences, a regenerative medicine and surgical instrument company, acquired the ACell for $400 million.
gold:hypernym
dbr:Columbia
skos:closeMatch
n13:grid.421889.e
prov:wasDerivedFrom
wikipedia-en:ACell?oldid=1072514399&ns=0
dbo:wikiPageLength
5286
foaf:isPrimaryTopicOf
wikipedia-en:ACell
Subject Item
dbr:Integra_LifeSciences
dbo:wikiPageWikiLink
dbr:ACell
Subject Item
dbr:Pig_bladder
dbo:wikiPageWikiLink
dbr:ACell
Subject Item
dbr:MatriStem
dbo:wikiPageWikiLink
dbr:ACell
dbo:wikiPageRedirects
dbr:ACell
Subject Item
wikipedia-en:ACell
foaf:primaryTopic
dbr:ACell